Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):142-149.
doi: 10.1158/1055-9965.EPI-20-0944. Epub 2020 Dec 11.
Don C Codipilly, Tarek Sawas, Lovekirat Dhaliwal, Michele L Johnson, Ramona Lansing , Kenneth K Wang, Cadman L Leggett, David A Katzka, Prasad G Iyer PMID: 33328255 DOI: 10.1158/1055-9965.EPI-20-0944
Background: Esophageal adenocarcinoma is a lethal cancer with rising incidence. There are limited data in younger (<50 years) patients with esophageal adenocarcinoma. We aimed to assess time trends in the incidence and outcomes of "young-onset" esophageal adenocarcinoma using a population-based database.
Methods: We queried the Surveillance, Epidemiology, and End Results 9 database to identify patients with esophageal adenocarcinoma between 1975 and 2015. Patients were stratified into three age strata:
Results: Esophageal adenocarcinoma incidence has increased in patients
Conclusions: Young-onset esophageal adenocarcinoma, while uncommon, is rising in incidence. Concerningly, the proportion of advanced disease continues to increase. Young-onset esophageal adenocarcinoma also presents at more advanced stages, resulting in poorer esophageal adenocarcinoma-free survival.
Impact: Patients with esophageal adenocarcinoma younger than 50 years present at more advanced stages with higher esophageal adenocarcinoma-specific mortality compared with older peers. Current diagnostic and management strategies for young-onset esophageal adenocarcinoma may need to be reevaluated..